Endo Pharms Inc patents expiration
1. Aveed patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7718640 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(2 years from now) | |
| US8338395 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 05, 2017 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: INJECTABLE;INTRAMUSCULAR
AVEED family patents
2. Megace Es patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6592903 | ENDO PHARMS INC | Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep, 2020
(3 years ago) | |
| US9101540 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(a day from now) | |
| US7101576 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(a day from now) | |
| US9107827 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(a day from now) | |
| US9101549 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(a day from now) | |
| US9040088 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(a day from now) | |
Drugs and Companies using MEGESTROL ACETATE ingredient
Market Authorisation Date: 05 July, 2005
Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)
Dosage: SUSPENSION;ORAL
MEGACE ES family patents
3. Nascobal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8940714 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Feb, 2024
(a month ago) | |
| US7404489 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Mar, 2024
(a month ago) | |
| US9415007 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Jul, 2024
(3 months from now) | |
| US7229636 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(3 months from now) | |
| US7879349 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(3 months from now) | |
| US8003353 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(3 months from now) | |
Drugs and Companies using CYANOCOBALAMIN ingredient
Market Authorisation Date: 31 January, 2005
Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin
Dosage: SPRAY, METERED;NASAL
NASCOBAL family patents